表紙
市場調查報告書

糖尿病腎病變 : 開發平台分析

Diabetic Nephropathy - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 192557
出版日期 內容資訊 英文 264 Pages
訂單完成後即時交付
價格
糖尿病腎病變 : 開發平台分析 Diabetic Nephropathy - Pipeline Review, H1 2020
出版日期: 2020年02月28日內容資訊: 英文 264 Pages
簡介

所謂糖尿病腎病變是由糖尿病引發的腎臟損傷。主要的症狀有蛋白尿,及腎小球濾過率低,高血壓等。致病的危險因子有肥胖症和高血壓、高脂肪血·高糖血、抽煙等。可用藥物兩用和改善飲食等方式緩和症狀。

本報告提供全球各國的糖尿病腎病變治療用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

糖尿病腎病變概要

治療藥的開發

  • 糖尿病腎病變開發中產品:概要
  • 糖尿病腎病變開發中產品:比較分析

各企業正在開發的糖尿病腎病變治療藥

大學/研究機關研究中的糖尿病腎病變治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

糖尿病腎病變治療藥:開發中的產品一覽(各企業)

糖尿病腎病變治療藥:研究中的產品一覽(大學/研究機關別)

糖尿病腎病變開發治療藥的企業

  • AbbVie Inc.
  • Antisense Therapeutics Limited
  • Arena Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bayer AG
  • BiOrion Technologies B.V.
  • Boehringer Ingelheim GmbH
  • Cellmid Limited
  • ChemoCentryx, Inc.
  • Concert Pharmaceuticals, Inc.
  • CSL Limited
  • 第一三共
  • Dimerix Bioscience Pty Ltd
  • Dong Wha Pharma Co., Ltd.
  • Dynamis Therapeutics, Inc.
  • Eli Lilly and Company
  • Galectin Therapeutics, Inc.
  • GenKyoTex S.A.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Glucox Biotech AB
  • GNI Group Ltd.
  • Islet Sciences, Inc.
  • Jenrin Discovery, Inc.
  • Johnson & Johnson
  • Mallinckrodt Plc
  • Mesoblast Limited
  • 田邊三菱製藥
  • MorphoSys AG
  • NephroGenex, Inc.
  • Noxxon Pharma AG
  • Omeros Corporation
  • 大塚集團
  • Pfizer Inc.
  • PhytoHealth Corporation
  • ProMetic Life Sciences Inc.
  • Serodus ASA
  • Shire Plc
  • 武田藥品工業
  • Theravance Biopharma, Inc.
  • Tobira Therapeutics, Inc.
  • Vascular Pharmaceuticals, Inc.
  • Vicore Pharma AB
  • XOMA Corporation

糖尿病腎病變:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • 11-RVIVIT
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • 11-RVIVIT
  • A-717
  • Antibodies to Inhibit Heparanase for Cancer
  • APD-371
  • APX-115
  • ASP-8232
  • ATL-1103
  • atrasentan hydrochloride
  • baricitinib
  • BI-703704
  • Biologic for Diabetic Nephropathy
  • BOT-191
  • C-21
  • canagliflozin
  • CCX-140
  • cenicriviroc mesylate
  • corticotropin
  • CS-3150
  • CSL-346
  • CTP-499
  • Cyndacel-M
  • DMX-250
  • Drugs to Activate Nrf2 for Diabetic Cardiomyopathy and Metabolic Disorders
  • DT-23552
  • DW-1029M
  • DYN-12
  • emapticap pegol
  • finerenone
  • gevokizumab
  • GKT-136901
  • GKT-831
  • GRMD-02
  • GW-610742
  • JD-5037
  • JNJ-39933673
  • Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications
  • Monoclonal Antibody to Inhibit Midkine for Cancer, Metabolic Disorders and Kidney Diseases
  • MOR-107
  • MPC-300IV
  • MT-3995
  • Nephrilin
  • oxypurinol
  • PBI-4050
  • PBI-4547
  • PF-00489791
  • PHN-033
  • pirfenidone
  • probucol
  • Pyridoxamine Dihydrochloride
  • selonsertib
  • SER-150
  • SHP-627
  • Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy
  • Small Molecules for Diabetic Nephropathy
  • Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders
  • Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy
  • SP-20202
  • TAK-272
  • TAK-648
  • TBE-31
  • TD-0714
  • VPI-2690B
  • VS-105
  • XRX-108
  • XRX-221

糖尿病腎病變治療藥:開發中產品的最新趨勢

糖尿病腎病變治療藥:開發暫停的產品

糖尿病腎病變治療藥:開發中止的產品

糖尿病腎病變相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12004IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy - Pipeline Review, H1 2020, provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape.

Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 20, 16, 27 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

TABLE OF CONTENTS

Introduction

  • Diabetic Nephropathy - Overview
  • Diabetic Nephropathy - Therapeutics Development
  • Diabetic Nephropathy - Therapeutics Assessment
  • Diabetic Nephropathy - Companies Involved in Therapeutics Development
  • Diabetic Nephropathy - Drug Profiles
  • Diabetic Nephropathy - Dormant Projects
  • Diabetic Nephropathy - Discontinued Products
  • Diabetic Nephropathy - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Diabetic Nephropathy, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Diabetic Nephropathy - Pipeline by Aibios Co Ltd, H1 2020
  • Diabetic Nephropathy - Pipeline by Algomedix Inc, H1 2020
  • Diabetic Nephropathy - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2020
  • Diabetic Nephropathy - Pipeline by Antisense Therapeutics Ltd, H1 2020
  • Diabetic Nephropathy - Pipeline by APT Therapeutics Inc, H1 2020
  • Diabetic Nephropathy - Dormant Projects, H1 2020
  • Diabetic Nephropathy - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Diabetic Nephropathy - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Diabetic Nephropathy - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Diabetic Nephropathy - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Diabetic Nephropathy, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020